Glaucoma, Neovascular Clinical Trial
Official title:
Intravitreal Ranibizumab (Lucentis®) for Neovascular Glaucoma- a Randomized Controlled Study
Neovascular glaucoma is a potentially blinding condition characterized by the growth of newvessels at the anterior part of the eye. This growth is driven by the overexpression of a protein called Vascular Endothelial Growth Factor (VEGF). That happens in diseases such as diabetic retinopathy or venous retinal occlusion, and lead to a fast increase in intraocular pressure (IOP). Traditional treatment include laser photocoagulation of the retina in order to decrease VEGF formation. The investigators postulate that the use of anti-VEGF intravitreal injections may accelerate recovery and decrease the need of surgery in cases of neovascular glaucoma.
This is a prospective, randomized controlled study that aims to evaluate the efficacy of
ranibizumab (Lucentis®) as an adjunct in the treatment of patients with neovascular
glaucoma.
28 patients with neovascular glaucoma (14 in the study group and 14 in the control standard
of care group) will be recruited at a single center- University of Sao Paulo Medical School
General Hospital. A complete ophthalmologic exam will be carried out, including the
obtention of an informed consent for eligible patients willing to participate on the study.
Patients will be randomly assigned to either standard of care- retinal laser
photocoagulation and clinical management of intraocular pressure with drops, or standard of
care plus intravitreal ranibizumab injections. Two injections will be performed 30 days
apart. The patients will be followed for 6 months.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01908816 -
An Open-label Extended Clinical Protocol of Ranibizumab to Evaluate Safety and Efficacy in Rare VEGF Driven Ocular Diseases.
|
Phase 3 | |
| Completed |
NCT03639675 -
Study to Learn How the Drug Aflibercept Works in in Japanese Patients With Increased Eye Pressure That is Caused by New Blood Vessels Growing in the Eye (Neovascular Glaucoma or NVG). Safety of the Drug and Patients' Tolerability of the Drug Injection is Also Studied
|
Phase 3 | |
| Not yet recruiting |
NCT05593354 -
MicroPulse TLT - UK Study
|
||
| Completed |
NCT03187418 -
Treatment Outcomes of MicroPulse Trans-scleral Cyclophotocoagulation in Uncontrolled Glaucoma
|
N/A | |
| Completed |
NCT02647515 -
Intravitreal Ranibizumab Injection as Adjuvant in the Treatment of Postvitrectomy Diabetic Vitreous Hemorrhage Accompanied by Neovascular Glaucoma
|
Phase 4 | |
| Enrolling by invitation |
NCT04381611 -
INTEGRAL Study: A Longitudinal Study of Surgeries and Lasers in Glaucoma: Long-term Results and Success Predictors Analysed From a Large-scale Retrospective and Prospective Glaucoma Register
|
||
| Completed |
NCT04215575 -
Baerveldt (BGI) Valve Versus Ahmed(AGV) Valve in Management of Difficult Glaucoma Cases
|
N/A | |
| Completed |
NCT01922154 -
Intravitreous Ranibizumab as Adjunctive Treatment for Trabeculectomy in Neovascular Glaucoma
|
Phase 4 | |
| Completed |
NCT04214847 -
The Outcome of Ahmed Glaucoma Valve in Difficult Glaucoma Cases
|
N/A | |
| Recruiting |
NCT03648814 -
Intracameral Versus Intravitreal Bevacizumab Injection in NVG: RCT
|
N/A | |
| Completed |
NCT02396316 -
Japanese Phase 3 Study of Aflibercept in Neovascular Glaucoma Patients
|
Phase 3 |